TELO
Telomir Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.04
−0.95%Next report
Analyst consensus
- Next report date
- Dec 2, 2026
- EPS estimate
- -$0.03
- Revenue estimate
- $500.0K
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.79
- EPS estimate
- -$0.07
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -264.7%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.07 | -$0.79 | Miss -1028.57% | — |
| May 14, 2026 | -$0.07 | -$0.03 | Beat 57.14% | — |
| Mar 17, 2026 | -$0.08 | -$0.06 | Beat 25.00% | — |
| Aug 14, 2025 | -$0.08 | -$0.17 | Miss -112.50% | — |
| Feb 4, 2025 | -$0.05 | -$0.10 | Miss -100.00% | $18.8M |
| Mar 31, 2022 | — | -$0.00 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 2, 2026